Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
322
Recruiting, any sponsor type, condition "sarcoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting322
- Completed1,043
322 trials
Showing 1 to 25, recently updated first.
National Cancer Institute (NCI)NIH
NCT04222413 · 116 participants (planned) · Start Oct 27, 2020 · Primary completion Dec 31, 2027
Drug: Metarrestin · For: Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor and 3 more
Sites: Fairway, Kansas; Bethesda, Maryland
Adcendo ApSIndustry
NCT06797999 · 270 participants (planned) · Start Jun 5, 2025 · Primary completion Feb 27, 2029
Drug: Antibody-drug conjugate (ADC) · For: Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Sites: Aurora, Colorado; Miami, Florida; New York, New York · 9 sites in all
Ain Shams UniversityAcademic, hospital or other
NCT07057765 · 40 participants (planned) · Start May 5, 2025 · Primary completion Nov 2027
Drug: Observational Assessment of Standard R-CHOP Treatment · For: DLBCL - Diffuse Large B Cell Lymphoma; Markers of Inflammation
Sites: Cairo, Egypt
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
National Cancer Institute (NCI)NIH
NCT06066138 · 30 participants (planned) · Start Nov 4, 2025 · Primary completion Jan 31, 2027
Drug: Atezolizumab · For: Locally Advanced Alveolar Soft Part Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Locally Advanced Non Small Cell Lung Cancer and 7 more
Sites: Bethesda, Maryland
Emory UniversityAcademic, hospital or other
NCT06492954 · 12 participants (planned) · Start Mar 2027 · Primary completion Jun 2027
Drug: Atezolizumab · For: Osteosarcoma; Pulmonary Recurrence of Osteosarcoma
Sites: Atlanta, Georgia; Houston, Texas
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasPivotal-lookingRecruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT06465199 · 265 participants (planned) · Start May 13, 2026 · Primary completion May 2033
Drug: Eflornithine (DFMO); AMXT 1501 Dicaprate · For: Atypical Teratoid/Rhabdoid Tumor; Embryonal Tumor With Multilayered Rosettes; Ewing Sarcoma and 4 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Hartford, Connecticut · 16 sites in all
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
- A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT07466316 · 342 participants (planned) · Start Jul 14, 2026 · Primary completion Jun 30, 2034
Drug: Cyclophosphamide; Dactinomycin and 3 more · For: Rhabdomyosarcoma
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 138 sites in all
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06422806 · 365 participants (planned) · Start Sep 11, 2024 · Primary completion Apr 18, 2032
Drug: Doxorubicin; Pembrolizumab · For: Metastatic Dedifferentiated Liposarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 and 3 more
Sites: Phoenix, Arizona; Tucson, Arizona; Dublin, California · 269 sites in all
National Cancer Institute (NCI)NIH
NCT04616560 · 55 participants (planned) · Start Mar 8, 2021 · Primary completion Dec 31, 2027
Drug: Trastuzumab Deruxtecan · For: Desmoplastic Small Round Cell Tumor; Osteosarcoma; Recurrent Desmoplastic Small Round Cell Tumor and 5 more
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 32 sites in all
National Cancer Institute (NCI)NIH
NCT05333458 · 27 participants (planned) · Start Aug 29, 2022 · Primary completion May 1, 2027
Drug: Atezolizumab; Selinexor · For: Advanced Alveolar Soft Part Sarcoma; Advanced Soft Tissue Sarcoma; Metastatic Alveolar Soft Part Sarcoma and 2 more
Sites: Los Angeles, California; Hartford, Connecticut; New Haven, Connecticut · 13 sites in all
- Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected TumorsRecruiting
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07374848 · 180 participants (planned) · Start Mar 2, 2026 · Primary completion Aug 2028
Drug: ZL-6201 · For: Solid Tumors; Sarcomas
Sites: Los Angeles, California; New Haven, Connecticut; Sarasota, Florida · 12 sites in all
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine LeiomyosarcomaPivotal-lookingRecruiting
Blokhin's Russian Cancer Research CenterAcademic, hospital or other
NCT07942168 · 100 participants (planned) · Start Jan 24, 2023 · Primary completion Jan 2027
Drug: Doxorubicin; Doxorubicin and 1 more · For: Leiomyosarcoma; Uterine Leiomyosarcoma
Sites: Moscow, Russia
National Cancer Institute (NCI)NIH
NCT04941274 · 111 participants (planned) · Start Sep 29, 2021 · Primary completion Mar 1, 2028
Drug: Abemaciclib · For: Kaposi Sarcoma
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT07308886 · 55 participants (planned) · Start Apr 8, 2026 · Primary completion Jan 31, 2036
Drug: CYT107 · For: Kaposi Sarcoma
Sites: Bethesda, Maryland
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Pivotal-lookingRecruiting
Intensity Therapeutics, Inc.Industry
NCT06263231 · 333 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2027
Drug: INT230-6; Eribulin and 2 more · For: Sarcoma,Soft Tissue
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 20 sites in all
- tTF-NGR Randomized Study - STSPivotal-lookingRecruiting
Universität MünsterAcademic, hospital or other
NCT05597917 · 126 participants (planned) · Start Oct 26, 2021 · Primary completion Dec 2030
Drug: Trabectedin; tTF-NGR · For: Soft Tissue Sarcoma
Sites: Augsburg, Germany; Bad Saarow, Germany; Berlin, Germany · 14 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07548177 · 33 participants (planned) · Start Apr 2, 2026 · Primary completion Dec 2028
Drug: Benmelstobart injection combined with Anlotinib hydrochloride capsule · For: Alveolar Soft Part Sarcoma
Sites: Beijing, China; Chongqing, China; Guangdong, China · 15 sites in all
National Cancer Institute (NCI)NIH
NCT05711615 · 30 participants (planned) · Start Feb 6, 2024 · Primary completion May 3, 2027
Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Peposertib · For: Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma and 9 more
Sites: Los Angeles, California; Aurora, Colorado; Miami, Florida · 16 sites in all
St. Jude Children's Research HospitalAcademic, hospital or other
NCT06023641 · 135 participants (planned) · Start Mar 13, 2024 · Primary completion Oct 2034
Drug: Vincristine; Dactinomycin and 5 more · For: Rhabdomyosarcoma
Sites: Palo Alto, California; Memphis, Tennessee; Fort Worth, Texas
Canadian Cancer Trials GroupResearch network
NCT07297667 · 30 participants (planned) · Start Aug 30, 2026 · Primary completion Dec 1, 2028
Drug: Fludarabine; Cyclophosphamide and 1 more · For: Alveolar Soft Part Sarcoma; Renal Cell Carcinoma; Triple Negative Breast Cancer
Sites: Calgary, Canada; Ottawa, Canada; Toronto, Canada · 4 sites in all
Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
NCT06235125 · 10 participants (planned) · Start Apr 8, 2024 · Primary completion Nov 1, 2027
Drug: Cytalux · For: Osteosarcoma; Pulmonary Metastasis; Fluorescence and 2 more
Sites: Chicago, Illinois
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsRecruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT06541262 · 104 participants (planned) · Start Oct 30, 2024 · Primary completion Nov 1, 2030
Drug: Silmitasertib; Irinotecan and 2 more · For: Neuroblastoma; Ewing Sarcoma; Osteosarcoma and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Oakland, California · 27 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.